Atlas Venture led a $100m seed and Series A round in Judo Bio.

Atlas Venture, an early-stage venture capital firm, led a $100m seed and Series A round in Judo Bio, a biotechnology company, with participation from The Column Group, TCG, Droia Ventures, Digitalis Ventures, Euclidean Capital, Alexandria Venture Investments and YK Bioventures. “The Judo team should be applauded for their achievements to date. In a short period, the company has developed a novel platform, demonstrated potent and selective gene knockdown in specific kidney regions, and constructed a pipeline of compelling programs that we are excited to see advanced towards the clinic,” Kevin Bitterman, Atlas Venture Partner.